Abstract:Objective: Review the studies that investigate the mechanisms underlying imatinib-resistant gastrointestinal stromal tumors (GIST). Background: GIST are the most common mesenchymal tumors of the gastrointestinal (GI) tract and the most common sarcoma in humans. GIST are thought to be arise from interstitial cells of Cajal (ICC), pacemaker and neuromodulator cells in the GI tract, as well as "fibroblast"-like cells, which are another type of interstitial cells of the gut wall and also known as telocyte or platelet-derived growth factor-alpha (PDGFRA)-positive cells. The majority of GIST harbor gain-of-function mutations in either KIT or PDGFRA, and these gain-of-function mutations are mutually exclusive and most often heterozygous. GIST are responsive to the KIT/PDGFRA tyrosine kinase inhibitor (TKI), imatinib, the standard first-line drug for advanced and metastatic GIST. However, imatinib alone does not eradicate GIST despite an initial clinical benefit, and more than 90% of GIST harbor imatinib-resistance. Although second and third-generation TKIs have been developed and are currently in clinical use, they are not curative for refractory and metastatic GIST due to the emergence of clones with drug-resistant mutations. Eradication of drug-resistant GIST will cure patients with refractory GIST. Several mechanisms may contribute to refractory GIST. These mechanisms are secondary mutations in KIT and/or PDGFRA, alternative activation of tyrosine kinases, stem cells for GIST and cellular quiescence, a reversible nonproliferating state in which cells retain the ability to reenter cell proliferation. Methods: We review our current optimal treatment approach for managing patients with advanced and refractory GIST. Conclusions: This review explores the novel and potential therapeutic approaches to combat drug-resistant GIST.

Research progress of non-coding RNA in gastrointestinal stromal tumor

An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

LncRNA-HOTAIR Activates Autophagy and Promotes the Imatinib Resistance of Gastrointestinal Stromal Tumor Cells Through a Mechanism Involving the Mir-130A/ ATG2B Pathway

Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor

[Molecular Mechanism of Gastrointestinal Stromal Tumors and Progress in Drug Research].

Research progress on the mechanism of imatinib resistance in gastrointestinal stromal tumor: from classical perspective to immune microenvironment perspective

Advances in Drug Therapy for Gastrointestinal Stromal Tumour

Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies

Analysis of Potential Circular RNAs in Regulating Imatinib Resistance of Gastrointestinal Stromal Tumor

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

Molecular Classification and Targeted Therapy of Gastrointestinal Stromal Tumors

New Developments in Gastrointestinal Stromal Tumor

The Potential circRNAs in Imatinib Resistance of GIST

A narrative review of imatinib-resistant gastrointestinal stromal tumors

Current status and progress in novel drug research for gastrointestinal stromal tumors

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update

Research Progress on Prognostic Factors of Gastrointestinal Stromal Tumor

[Treatment Progress of Gastrointestinal Stromal Tumor].

The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux